申请人:Sankyo Company, Limited
公开号:EP1375482A1
公开(公告)日:2004-01-02
Compounds of general formula (1) and pharmacologically acceptable salts thereof:
[wherein
R1 represents a hydrogen atom, a halogen atom, an alkyl group or a hydroxyl group;
R2 represents a hydrogen atom or a halogen atom;
R3 represents a hydrogen atom, an alkyl group which may be substituted, an aralkyl group, an alkylcarbonyl group which may be substituted, an alkylsulfonyl group which may be substituted or the like;
each of R4 and R5 represents a hydrogen atom, a halogen atom, an alkyl group which may be substituted, a carbamoyl group or the like;
R6 represents a heterocycle or the like;
each of R7 and R8 represents a hydrogen atom, an alkyl group or the like;
n represents 0, 1 or 2]
exhibit excellent activated blood coagulation factor X inhibitory activity and are useful for the prevention or treatment of blood coagulation-related diseases.
通式(1)化合物及其药理学上可接受的盐类:
其中
R1 代表氢原子、卤素原子、烷基或羟基;
R2 代表氢原子或卤素原子
R3 代表氢原子、可被取代的烷基、芳烷基、可被取代的烷基羰基、可被取代的 烷磺酰基或类似基团;
R4 和 R5 各自代表氢原子、卤素原子、可被取代的烷基、氨基甲酰基或类似基团;
R6 代表杂环或类似物;
R7 和 R8 各自代表氢原子、烷基或类似物;
n 代表 0、1 或 2]
这些化合物具有优异的活化血液凝固因子 X 抑制活性,可用于预防或治疗血液凝固相关疾病。